Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Menu

    Relacorilant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corcept to present late-breaking data from Rosella trial at ASCO Meeting
    Corcept to present late-breaking data from Rosella trial at ASCO Meeting

    23 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250422468615/en/CORCEPT-TO-PRESENT-LATE-BREAKING-DATA-FROM-PIVOTAL-PHASE-3-ROSELLA-TRIAL-OF-RELACORILANT-IN-PLATINUM-RESISTANT-OVARIAN-CANCER-AT-ASCO-2025

    BUSINESSWIRE
    23 Apr 2025
    Share Share
    Corcept Starts Trial in Platinum-Resistant Ovarian Cancer
    Corcept Starts Trial in Platinum-Resistant Ovarian Cancer

    07 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250407805321/en/Corcept-Initiates-Trial-of-Relacorilant-Plus-Nab-Paclitaxel-and-Bevacizumab-in-Patients-With-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    07 Apr 2025
    Share Share
    FDA Files Corcept's NDA for Relacorilant in Hypercortisolism
    FDA Files Corcept's NDA for Relacorilant in Hypercortisolism

    03 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250303227690/en

    BUSINESSWIRE
    03 Mar 2025
    Share Share
    Corcept Submits NDA for Relacorilant in Hypercortisolism
    Corcept Submits NDA for Relacorilant in Hypercortisolism

    30 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241230947567/en

    BUSINESSWIRE
    30 Dec 2024
    Share Share
    Corcept’s Relacorilant Ph 3 Shows Cardiometabolic Improvements
    Corcept’s Relacorilant Ph 3 Shows Cardiometabolic Improvements

    16 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241216461773/en

    BUSINESSWIRE
    16 Dec 2024
    Share Share
    Corcept's GRACE Relacorilant Hypercortisolism Phase 3 Data Presented
    Corcept's GRACE Relacorilant Hypercortisolism Phase 3 Data Presented

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892174/0/en/Corcept-Therapeutics-Announces-Presentations-of-Results-of-Pivotal-Phase-3-GRACE-Trial-Evaluating-Relacorilant-in-Patients-with-Hypercortisolism-Cushing-s-Syndrome.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share